The FDA granted Gilead Sciences approval to use Trodelvy (sacituzumab govitecan-hziy) in first-line triple-negative breast cancer (TNBC) regardless of PD-L1 status. The updated label now covers patients ineligible for PD-1/L1 inhibitors using Trodelvy alone, while PD-L1-positive patients with a combined positive score (CPS) of at least 10 can receive Trodelvy in combination with Merck’s Keytruda. This approval broadens the competitive field for TROP2 antibody-drug conjugates in early treatment settings and follows recent front-line moves in the class, setting up additional market-share battles as rival regimens mature.